Evidence map›Paper›PMID 35237922›Full record

ArticlePharmaceutical research2022

Safety and Pharmacokinetics of Intranasally Administered Heparin.

Hannah M Harris, Katherine L Boyet, Hao Liu, Rohini Dwivedi, Nicole M Ashpole, Ritesh Tandon, Gene L Bidwell, Zhi Cheng, Lauren A Fassero, Christian S Yu and 8 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Hannah M HarrisDepartment of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi, 38677, USA.
Katherine L BoyetDepartment of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi, 38677, USA.
Hao LiuDepartment of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi, 38677, USA.
Rohini DwivediDepartment of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi, 38677, USA.
Nicole M AshpoleDepartment of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi, 38677, USA.
Ritesh TandonDepartment of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi, 38677, USA.
Gene L BidwellDepartment of Neurology, University of Mississippi Medical Center, Jackson, Mississippi, 39216, USA.
Zhi ChengDepartment of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi, 38677, USA.
Lauren A FasseroDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, Mississippi, 39216, USA.
Christian S YuDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, Mississippi, 39216, USA.
Vitor H PominDepartment of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi, 38677, USA.
Dipanwita MitraDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, Mississippi, 39216, USA.
Kerri A HarrisonNational Center for Natural Products Research, University of Mississippi, Oxford, Mississippi, 38677, USA.
Eric DahlNational Center for Natural Products Research, University of Mississippi, Oxford, Mississippi, 38677, USA.
Bill J GurleyNational Center for Natural Products Research, University of Mississippi, Oxford, Mississippi, 38677, USA.
Arun Kumar KothaDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, Oxford, Mississippi, 38677, USA.
Mahavir Bhupal ChouguleDepartment of Pharmaceutics and Drug Delivery, University of Mississippi, Oxford, Mississippi, 38677, USA.
Joshua S SharpDepartment of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi, 38677, USA. jsharp@olemiss.edu.ORCID http://orcid.org/0000-0002-0115-0276
University of Mississippi · USUniversity of Mississippi Medical Center · USMercer University · US

Funding

Tracking Glycosylation State with Fluorinated Glycosides ProbesP20GM130460 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI Joshua S Sharp · 2020 to 2026
$17.9M
Pilot Project ProgramP30GM122733 · NIGMS · UNIVERSITY OF MISSISSIPPI · PI MAJUMDAR, SOUMYAJIT · 2018 to 2022
$5.3M
NIGMS NIH HHS P20 GM130460NIGMS NIH HHS P30 GM122733
6 · The paper itself

Abstract

purposeIntranasally administered unfractionated heparin (UFH) and other sulfated polysaccharides are potential prophylactics for COVID-19. The purpose of this research was to measure the safety and pharmacokinetics of clearance of intranasally administered UFH solution from the nasal cavity.

methodsDouble-blinded daily intranasal dosing in C57Bl6 mice with four doses (60 ng to 60 μg) of UFH was carried out for fourteen consecutive days, with both blood coagulation measurements and subject adverse event monitoring. The pharmacokinetics of fluorescent-labeled UFH clearance from the nasal cavity were measured in mice by in vivo imaging. Intranasal UFH at 2000 U/day solution with nasal spray device was tested for safety in a small number of healthy human subjects.

resultsUFH showed no evidence of toxicity in mice at any dose measured. No significant changes were observed in activated partial thromboplastin time (aPTT), platelet count, or frequency of minor irritant events over vehicle-only control. Human subjects showed no significant changes in aPTT time, international normalized ratio (INR), or platelet count over baseline measurements. No serious adverse events were observed. In vivo imaging in a mouse model showed a single phase clearance of UFH from the nasal cavity. After 12 h, 3.2% of the administered UFH remained in the nasal cavity, decaying to background levels by 48 h.

conclusionsUFH showed no toxic effects for extended daily intranasal dosing in mice as well as humans. The clearance kinetics of intranasal heparin solution from the nasal cavity indicates potentially protective levels for up to 12 h after dosing.

Indexed as

COVID-19HeparinAnimalsAnticoagulantsHumansMiceMice, Inbred C57BLPartial Thromboplastin TimeAnticoagulantsHeparinCovid-19heparinintranasal deliverySARS-CoV-2

Identifiers

PMID35237922
PMCPMC8890767
OpenAlexW4221034502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.